Ep 324 - The Cannabinoid Science Nobody is Talking About

CannaInsider - Interviews with the Business Leaders of The Legal Cannabis, Marijuana, CBD Industry

Inhalt bereitgestellt von Matthew Kind. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Matthew Kind oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.

3+ y ago 43:58

MP3•Episode-Home

Archivierte Serien ("Inaktiver Feed" status)

When? This feed was archived on April 28, 2023 03:56 (12M ago). Last successful fetch was on July 04, 2022 06:00 (2y ago)

Why? Inaktiver Feed status. Unsere Server waren nicht in der Lage einen gültigen Podcast-Feed für einen längeren Zeitraum zu erhalten.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

We just reached possibly one of the largest milestones in creating pure, consistent cannabinoids in a lab. Here to tell us about it is Kevin Chen of Hyasynth Bio.

Learn more at https://hyasynthbio.com

Key Takeaways:

[1:32] An inside look at Hyasynth Bio and its work creating biosynthesized cannabis compounds

[3:05] Hyasynth Bio’s first product, an ultra-pure CBD oil created using cultured cannabinoids

[7:44] How Hyasynth Bio is improving CBD production in terms of both speed and purity

[9:12] Why multinational companies are gravitating towards biosynthesized cannabinoids for better consistency and supply chain performance

[13:14]

[16:55] How biosynthesized cannabinoids are paving the way for international cannabis brands and which products Kevin believes will go global first

[21:23] How cellular agriculture is giving us better access to rare cannabinoids

[27:48] Why cellular agriculture is easier to automate and how this might influence prices in the cannabis industry

[32:21] Hyasynth Bio’s strategy to profit primarily through intellectual property licensing

[36:24] Where Hyasynth Bio currently is in the capital-raising process

181 Episoden

#Trading #Business #Cannabis #Cannabisseeds #Investing #Marijuana #Marijuanaseeds #Medicalcannabis #Medicalmarijuana #Mmj #Matthew Kind #Dispensary #Edible #Legal